Ekso Bionics Holdings, INC 8-K filings

ChronoScale Corporation has successfully completed a holding company formation transaction, creating ChronoScale Holdings Corporation as the new parent entity without shareholder dilution.

ChronoScale Corporation (formerly Ekso Bionics Holdings, Inc.) has filed an amendment to its Form 8-K to include financial statements and pro forma information following its business combination with Applied Digital Cloud Corporation.

ChronoScale Corporation announced the expansion of its Board of Directors to eight members with the appointment of Andrew Cordell Schaap, who will also serve on the Audit and Related Party Transactions Committees.

ChronoScale Corporation has entered into a $100 million unsecured demand grid promissory note with Applied Digital Corporation for working capital.

ChronoScale Corporation announced its Board of Directors has committed to divesting its wholly owned subsidiary, Ekso Bionics, Inc., to concentrate solely on its cloud business.

ChronoScale Corporation has amended executive phantom stock unit awards to allow for equity-based settlement following a change in control.

Ekso Bionics Holdings, Inc. has completed its business combination with Applied Digital Cloud Corporation, rebranded as ChronoScale Corporation, and secured a $15.75 million PIPE investment.

Ekso Bionics Holdings, Inc. is taking steps to complete its business combination with Applied Digital Cloud Corporation, rebranding as ChronoScale Corporation and listing on Nasdaq under the ticker CHRN.

Ekso Bionics Holdings, Inc. announced a definitive agreement to combine with Applied Digital Cloud Corporation, a subsidiary of Applied Digital Corporation, and will change its name to ChronoScale Corporation, alongside preliminary Q4 2025 financial results.

Ekso Bionics Holdings, Inc. completed a private placement of Series B Convertible Preferred Stock and warrants, raising approximately $5.3 million in net proceeds for working capital.

Ekso Bionics announced a non-binding term sheet to combine with Applied Digital's cloud business, forming ChronoScale Corporation, an AI compute platform.

Ekso Bionics Holdings, Inc. announced new equity awards and updated severance agreements for three key executives to enhance retention and align with strategic goals.

Ekso Bionics Holdings, Inc. announced a registered direct offering of 769,490 common shares at $4.81 each, expecting net proceeds of $3.2 million for general corporate purposes.

Ekso Bionics reports improved third-quarter financial results and announces exploration of strategic transactions, including potential acquisitions or sale of current business.

Ekso Bionics Holdings, Inc. secured a new $2.0 million secured term loan from B. Riley Commercial Capital, LLC, simultaneously paying off and terminating its previous $2.0 million loan with Banc of California.

Ekso Bionics Holdings, Inc. announced significantly lower second-quarter 2025 revenue and increased net loss, primarily due to short-term delays in Enterprise Health device sales, despite growth in Personal Health products and strategic AI initiatives.

Ekso Bionics has updated the effective date of its previously approved 1-for-15 reverse stock split to June 2, 2025, to increase its stock price and regain Nasdaq compliance.

Ekso Bionics will implement a 1-for-15 reverse stock split, effective May 27, 2025, to increase its stock price and regain compliance with Nasdaq's minimum bid price requirement.

Ekso Bionics announced its Q1 2025 financial results, showing a decrease in revenue but improved operating cash burn and strategic partnerships.

Ekso Bionics Holdings, Inc. incentivizes an existing warrant holder to exercise their warrants early by offering new warrants in exchange.

Ekso Bionics announced record fourth-quarter revenue and improved gross margins in its full-year 2024 financial results, highlighting growth in exoskeleton technology for medical and industrial use.

Ekso Bionics anticipates record revenue for Q4 2024, with preliminary results showing revenue between $5.0 and $5.1 million.

Ekso Bionics Holdings, Inc. has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, putting its listing at risk.

Ekso Bionics announced its third quarter 2024 financial results, including revenue of $4.1 million and the achievement of initial CMS reimbursement for its Ekso Indego Personal device.

Ekso Bionics Holdings, Inc. successfully closed a public offering, raising approximately $5.1 million in net proceeds through the sale of common stock and warrants.

Ekso Bionics reported record quarterly sales of $5.0 million in the second quarter of 2024, alongside a gross margin of 53%.

Ekso Bionics has amended its initial 8-K filing to disclose its decision to hold an annual stockholder advisory vote on executive compensation.

Ekso Bionics held its 2024 Annual Meeting of Stockholders, electing five directors, extending its equity incentive plan, and ratifying its independent auditors.

Ekso Bionics announced its first quarter 2024 financial results, highlighted by a Medicare reimbursement determination and a gross margin of 52%.

Ekso Bionics reported record annual revenue of $18.3 million for 2023, a 42% increase year-over-year, driven by strong demand for its EksoHealth devices.